

Development of a Stable Cell Line, Overexpressing Human T-cell Immunoglobulin Mucin 1

Mina Ebrahimi ^{1,2,3}, Tohid Kazemi ², Mazdak Ganjalikhani-hakemi ^{4,*}, Jafar Majidi ², Hossein Khanahmad ^{5,**}, Ilnaz Rahimmanesh ⁵, Vida Homayouni ⁴, Shirin Kohpayeh ⁴

¹Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

²Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

³Tabriz University of Medical Sciences, Tabriz, Iran

⁴Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

⁵Department of Genetic and Molecular Biology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

*Corresponding author: Mazdak Ganjalikhani-hakemi, Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. Tel: +98-3137929082, Fax: +98-3137929031, E-mail: mghakemi@med.mui.ac.ir

**Co-Corresponding author: Hossein Khanahmad, Department of Genetic and Molecular Biology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. Tel: +98-3137929087, Fax: +98-3136688597, E-mail: khanahmad@med.mui.ac.ir

Received: September 19, 2015; **Revised:** November 12, 2015; **Accepted:** November 24, 2015

Background: Recent researches have demonstrated that human T-cell immunoglobulin mucin 1 (TIM-1) glycoprotein plays important roles in regulation of autoimmune and allergic diseases, as well as in tumor immunity and response to viral infections. Therefore, targeting TIM-1 could be a potential therapeutic approach against such diseases.

Objectives: In this study, we aimed to express TIM-1 protein on Human Embryonic kidney (HEK) 293T cell line in order to have an available source of the TIM-1 antigen.

Materials and Methods: The cDNA was synthesized after RNA extraction from peripheral blood mononuclear cells (PBMC) and TIM-1 cDNA was amplified by PCR with specific primers. The PCR product was cloned in pcDNATM3.1/Hygro (+) and transformed in *Escherichia coli* TOP 10 F'. After cloning, authenticity of DNA sequence was checked and expressed in HEK 293T cells. Finally, expression of TIM-1 was analyzed by flow cytometry and real-time PCR.

Results: The result of DNA sequencing demonstrated correctness of TIM-1 DNA sequence. The flow cytometry results indicated that TIM-1 was expressed in about 90% of transfected HEK 293T cells. The real-time PCR analysis showed TIM-1 mRNA expression increased 195-fold in transfected cells compared with un-transfected cells.

Conclusions: Findings of present study demonstrated the successful cloning and expression of TIM-1 on HEK 293T cells. These cells could be used as an immunogenic source for production of specific monoclonal antibodies, nanobodies and aptamers against human TIM-1.

Keywords: Cloning; Gene expression; HEK 293T; Immunogenic source; TIM-1

1. Background

TIM-1 is a type I membrane glycoprotein expressed on wide variety of cells consisted of T helper (Th) cells, B cells, mast cells, macrophages and kidney proximal tubular epithelial cells (1, 2). TIM-1, also known as hepatitis A virus cellular receptor-1 (HAVCR-1) and kidney injury molecule-1 (KIM-1), is considerably upregulated in proximal tubular epithelial cells of kidney following ischemic and toxic injury (3).

Human TIM-1 gene is located on 5q32.2 locus,

which is a region linked with susceptibility to asthma and allergy, and also is highly polymorphic among TIM gene family members (4, 5). Structurally, TIM-1 include an NH₂-terminal IgV-like domain with an N-linked glycosylation site, a mucin domain containing many O-linked glycosylation sites, a transmembrane domain, and a COOH-terminal short cytoplasmic domain (6).

TIM-1 protein as a co-stimulatory molecule regulates the expansion and effector functions of T helper

cells, particularly Th-2 immune responses (7, 8). Thus, associations between TIM-1 and allergic diseases are evident that makes it a major worldwide health issue (5). Moreover, TIM-1 plays critical role in Th-1 and Th-17 cell homing into the central nervous system (CNS). Thus, TIM-1 might be an important tool to achieve selective tissue homing of T cells in neurodegenerative disorders like multiple sclerosis (MS) (9). TIM-1 also regulates responses to viral infections and homeostasis of tumor microenvironment (2, 10). TIM-1 as a phosphatidylserine receptor on the surface of antigen-presenting cells helps in the detection and removal of apoptotic cells (2, 11). Filoviruses, ebolavirus, alphaviruses and baculoviruses use TIM-1 as a receptor for their entry to host cells (12-14). Phosphatidylserine on the viral envelope through interaction with TIM-1 enhances infection by these viruses (10, 15).

Therefore, interference with TIM-1 signaling, stimulating or blocking TIM-1 activity offers a novel approach for potential treatments for T cell-mediated diseases (9, 16). For example, blocking TIM-1 would inhibit Th-2 proliferation and cytokine production in allergic diseases (7). Also, blocking TIM-1 might be useful for preventing entry of Th1 and Th17 cells to CNS in order to help for treatment of multiple sclerosis (9).

2. Objectives

Anti-human monoclonal antibody, nanobody and aptamer could be considered as novel therapeutic agents for manipulation of TIM-1 associated immune-disregulations. Producing such agents requires stable source over-expression of TIM-1 antigen on a suitable cell line; not only for having an available source of the antigen, but also to achieve proper folding in TIM-1 protein structure. Hence, we aimed to produce a human TIM-1 expressing cell line using HEK 293T cells.

3. Materials and Methods

3.1. Cells and Bacteria

HEK 293T cells were purchased from Pasteur Institute of Iran and cultured in DMEM (Sigma-Aldrich, St., MO, USA) medium supplemented with 1% (w/v) penicillin/streptomycin (Gibco BRL, Karlsruhe, Germany) and 10% FBS (Sigma-Aldrich, St., MO, USA) in 5% CO₂ at 37°C. *E. coli* TOP 10 F' was purchased from Pasteur Institute of Iran and cultured in Luria Bertani (LB) culture medium (Sigma-Aldrich, St., MO, USA) containing 100 µg.mL⁻¹ tetracycline (Sigma-Aldrich, St., MO, USA).

3.2. PBMC Isolation

PBMC were isolated from heparinized whole blood samples using gradient centrifugation in Ficoll-Paque solution according to its manufacturer's instruction (Sigma-Aldrich, St., MO, USA).

3.3. RNA Extraction and cDNA Synthesis

Total RNA was extracted from PBMC using RNX kit (CinnaGen, Inc, Iran) based on the manufacturer's protocol. Using spectrophotometry and electrophoresis, quantity and quality of the extracted RNA were measured. The extracted RNAs were treated with *DNase I* (Thermo Fisher Scientific, Inc., MA, USA) and cleaned up with DNA extraction kit (Bioneer Inc., Seoul, South Korea) according to the manufacturer's instruction. cDNA was synthesized from 1 µg of the total RNA using first strand cDNA synthesis kit (Thermo Fisher Scientific, Inc., MA, USA) as instructed by the manufacturer.

3.4. TIM-1 Amplification

PCR was carried out on the cDNA for specific amplification of TIM-1 using designed specific primer: TIM-1-forward containing *NheI* restriction site

Table 1. Oligonucleotide primers using in PCR

Name	Sequences (5'-3')	Length (bp)	Tm (°C)
TIM-1	Forward: GCTAGCATGCATCCTCAAGTGGTC	24	63.8
	Reverse: CTCGAGTTAGTCCGTGGCATAAAG	24	61.2
pcDNA	Forward: ACTAGAGAACCCACTGCTTACTG	23	60.6
	Reverse: ATGGCTGGCAACTAGAAGG	19	56.7
RTIM	Forward: ACATAGTCTACTGACGGCCAATACC	25	61.9
	Reverse: CTCGAGTTAGTCCGTGGCATAAAGAC	26	63.2
β-actin	Forward: TTCGAGCAAGAGATGGCCA	19	59
	Reverse: CACAGGACTCCATGCCAG	19	60

at 5' end, and TIM-1-reverse containing *Xho*I restriction site at 5' end (Table 1). The PCR program started with 1 cycle at 95°C for 4 min, continued by 30 cycles at 95°C for 30 sec, 58°C for 30 s and 72°C for 2 min and 40 s, and ended with 1 cycle at 72°C for 10 min in a thermo cycler (Bio-Rad Laboratory, CA, USA). PCR products were electrophoresed on 1% (w/v) agarose and purified using Gel Purification kit (Bioneer Inc., Seoul, South Korea).

3.5. Cloning of TIM-1 cDNA

The pcDNATM3.1/Hygro (+) (100 ng.mL⁻¹) (Pasteur Institute, Iran) and TIM-1 amplicons (120 ng.μL⁻¹) were separately digested with *Xho*I and *Nhe*I enzymes (Thermo Fisher Scientific, Inc., MA, USA) according to the manufacturer's instruction. The digestion products (backbone of pcDNATM3.1/Hygro (+) and TIM-1 PCR product) were electrophoresed on 1% agarose and gel purified. Linearized pcDNATM3.1/Hygro (+) and TIM-1 were ligated using T4 DNA ligase enzyme (Thermo Fisher Scientific, Inc., MA, USA) according to the manufacturer's instruction. Ligation product was transformed into chemically competent *E. coli* TOP 10 F' using heat shock method (17). The pcDNATM3.1/Hygro (+) contains ampicillin resistance gene, therefore, *E. coli* TOP 10 F' bacteria could growth in LB culture medium with ampicillin as a selection marker.

To confirm the transfected clones, DNA sequencing was performed using a specific primer: pcDNA forward and reverse (Table 1).

3.6. Linearization of pcDNA/TIM-1

The pcDNA/TIM-1 plasmid was extracted with plasmid extraction kit (SolGent Co., Ltd., Deajaon, Korea). The extracted pcDNA/TIM-1 was linearized using *Bgl* II enzyme (Thermo Fisher Scientific, Inc., MA, USA) according to the manufacturer's instruction. After electrophoresis of the product on 1% agarose, the linear plasmid was gel purified.

3.7. Transfection

Transfection was performed using TurboFect reagent (Thermo Fisher Scientific, Inc., MA, USA) based on the provided protocol. Prior transfection (24 h earlier), 1×10⁶ HEK 293T cells were sub-cultured in two culture flasks so that confluency of the cells on the time of transfection was 60-70%. The linear pcDNA/TIM-1 plasmid (7.5 μg) were added to 750 μL serum free-DMEM medium, suspended by pipetting, and incubated for 2 min. About 15 μL of TurboFect

reagent was added to the plasmid suspension and incubated for 15-20 min at 22°C. The content of the tube was added to the cell culture flask drop-wise, mixed by swirling and incubated at 37°C overnight. In parallel, HEK 293T cells were transfected by linear pcDNA devoid of TIM-1 cDNA as control (mock transfection). On the next day, culture medium was refreshed. Following transfection, the cells were treated with 175 μg.mL⁻¹ hygromycin at day 3 (Roche Diagnostics, Indianapolis, IN, USA) to select the transfected cells.

3.8. Polymerase Chain Reaction (PCR) on HEK 293T Genomic DNA

To confirm the integration of linear pcDNA/TIM-1 into genome of HEK 293T cells, one month after transfection, genomic DNA of the transfected and un-transfected cells were extracted by DNA extraction kit (Genetbio, Deajaon, Korea) according to the manufacturer's instruction. PCR with pcDNA forward and reverse primers (Table 1) was carried out. The PCR program was started with 1 cycle at 94°C for 3 min, continued by 30 cycles at 94°C for 30 sec, 58°C for 30 sec and 72°C for 1 min and 30 sec, and ended with 1 cycle at 72°C for 10 min in a thermo cycler (Bio-Rad Laboratory). Genomic DNA of un-transfected HEK 293T cells was used as the negative control. PCR products of the control and the positive samples were analyzed by electrophoresis on 1% agarose gel. Expression of human TIM-1 in HEK 293T cell line was examined by flow cytometry and real-time quantitative PCR methods.

3.9. Flow Cytometry

Transfected and control cells were placed in 2 distinct flow cytometry tubes (suspension of 1×10⁶ cells/200 μL medium in each tube), 30 days following transfection. The cells were stained with 1 μL PE conjugated monoclonal anti-TIM-1 antibody (Biolegend, Inc., CA, USA), and with appropriate isotype control antibody (Biolegend, UK), separately. Cells were evaluated using FACS Callibur flow cytometry (BD bioscience, NJ, USA). The flow cytometric data were analysed by Cell quest pro software (IBM, CA, USA).

3.10. Real-Time Quantitative PCR

Total RNA of selected cells was isolated and cDNA was synthesized as described above. Primers was designed, RTIM forward and reverse, and β-actin-forward and reverse (Table 1). Real-time PCR was performed in a total volume of 20 μL in the StepOnePlusTM real-time PCR system (AB Applied

Biosystems, CA, USA) using SYBR[®] Premix Ex Taq (Takara Bio Inc., Otsu, Shiga, Japan) with the following program: 1 cycle 95°C for 10 min, continued by 40 cycles at 95°C for 15 sec and 60°C for 1 min. Data analysis was performed using 2^{-ΔΔCt} method (18). The results were normalized against β-actin expression level as a reference gene (19). All the reactions were performed in triplicate.

3.11. Statistical Analyses

The results were analyzed by SPSS 20 (Chicago, IL, USA) software. Mann-Withney U nonparametric test used to compare the results of groups. All the qPCR results were reported as Mean±SD (standard deviation) and mean was obtained from three identical repeats of each test.

4. Results

4.1. Amplifying TIM-1 cDNA

For the purpose of producing a human TIM-1 expressing cell line, we needed the human TIM-1 encoding cDNA. TIM-1 molecule expresses on T helper cells, B cells, mast cells and macrophages. Therefore, PBMC




Figure 1. Amplification of specific band for human TIM-1 cDNA using Pfu DNA polymerase. Lane 1 and 2, TIM-1 fragments with size of 1107 bp. Lane SM, DNA size marker (1kb)

could be an appropriate source for this purpose. After amplification of TIM-1 cDNA with specific primers bearing *NheI* and *XhoI* specific restriction sites, agarose gel electrophoresis of PCR product demonstrated a 1107 bp band (1095 bp for TIM-1 cDNA and 12 bp for two restriction sites) (Figure 1).

Homo sapiens hepatitis A virus cellular receptor 1 (HVACR1), transcript variant 1, mRNA
Sequence ID: ref[NM 012206.3] Length: 1713 Number of Matches: 1

Range 1: 299 to 1393		GenBank Graphics		▼ Next Match ▲ Previous Match
Score	Expect	Identities	Gaps	Strand
2023 bits (1095)	0.0	1095/1095(100%)	0/1095(0%)	Plus/Plus
Query 1	ATGCATCCTCAAGTGGTCATCTTAAGCCTCATCCTACATCTGGCAGATTCTGTAGCTGGT			60
Sbjct 299	ATGCATCCTCAAGTGGTCATCTTAAGCCTCATCCTACATCTGGCAGATTCTGTAGCTGGT			358
Query 61	TCTGTAAAGGTTGGTGGAGAGGCAGGTCATCTGTACACTACCCCTGCCACTACAGTGGG			120
Sbjct 359	TCTGTAAAGGTTGGTGGAGAGGCAGGTCATCTGTACACTACCCCTGCCACTACAGTGGG			418
Query 121	GCTGTCACATCCATGTGCTGGAATAGAGGCTCATGTTCTCTATTACATGCCAAAATGGC			180
Sbjct 419	GCTGTCACATCCATGTGCTGGAATAGAGGCTCATGTTCTCTATTACATGCCAAAATGGC			478
.....				
Query 1021	CAAAATGCAGTTGAAAAGGAAGTCCAAGCAGAAGACAATATCTACATTGAGAATAGTCTT			1080
Sbjct 1319	CAAAATGCAGTTGAAAAGGAAGTCCAAGCAGAAGACAATATCTACATTGAGAATAGTCTT			1378
Query 1081	TATGCCACGGACTAA	1095		
Sbjct 1379	TATGCCACGGACTAA	1393		

Figure 2. Nucleotide sequence alignment of cloned TIM-1at NCBI. Cloned TIM-1 sequence showed complete identity with human TIM-1 reference sequence. Only 5' to 3' ends of sequence have been briefly shown

4.2. Sequencing of pcDNA/TIM-1

After transformation of pcDNA/TIM-1 construction into competent *E. coli* TOP 10 F' bacteria, to confirm cloning of pcDNA/TIM-1 construction, DNA sequencing proved the presence of similar sequence with human TIM-1 reference sequence in the recombinant plasmid (Figure 2).

4.3. Expression of Human TIM-1 Protein

Following transfection of HEK 293T cells with linear pcDNA/TIM-1, to assess integration of linear pcDNA/TIM-1 into the genome of HEK 293T cells, PCR was performed and gel electrophoresis demonstrated the presence of pcDNA/TIM-1 in HEK 293T genomic DNA (band of 1240 bp) (Figure 3). The results of flow cytometry showed 88.15% of transfected cells expressed TIM-1 protein on their own surfaces. On the other hand, surface staining of un-transfected and mock transfection cells have no expression of TIM-1 (1.72 and 1.59%, respectively) (Figure 4). Real-time PCR results were in parallel with flow cytometry results revealed that levels of TIM-1 expression increased up to 195-fold ($p < 0.05$) (Figure 5).

5. Discussion

Considering the role of the TIM-1 in development of autoimmune diseases and allergy, regulation of




Figure 3. Gel electrophoresis of PCR product related to genomic DNA of transfected cells. Lane 1, untransfected HEK 293T cells, Lane SM, DNA size marker (1kb), Lane 3 and 4, a 1240 bp band of integrated human TIM-1

rolling of T cell subsets particularly Th1 and Th17 cell homing into the central nervous system (CNS), homeostasis of tumor microenvironment and receptor for virus entrance into host cells (2, 8-10), TIM-1 could be considered as a target for therapy of T cell-mediated diseases and virus infection using its specific monoclonal antibody, nanobody or aptamer (7, 15).




Figure 4. Flow cytometric analysis. Transfected cells displayed significantly positive signal, whereas mock transfected and untransfected cells showed no positive signal. A: pcDNA/TIM-1 transfected HEK 293T. B: Mock transfected HEK 293T. C: untransfected HEK 293T. FL2: Anti human TIM-1-PE




Figure 5. Real-time quantitative PCR analysis. TIM-1 column represents human TIM-1 mRNA expression level in transfected cells with linearized pcDNA/TIM-1 and control column represents human TIM-1 mRNA expression in untransfected ones. The results are represented as mean±SD (n=3); *p<0.05 versus control cells

Several anti-TIM-1 monoclonal antibodies have been used in treatment of experimental autoimmune diseases, allergy and viral infections. Xiao *et al.* (20) using anti-TIM-1 antibodies showed that these antibodies could have a dual function: inhibiting and increasing of T cell responses in autoimmune encephalomyelitis. The results of Encinas *et al.* (21) research indicated that anti-TIM-1 antibody can decrease Th2 responses in a mouse model of asthma. Study of Soo Hoo *et al.* (22) showed that TIM-1 antibodies caused induction of cellular proliferation and IFN- γ production against influenza virus infection.

The cells over-expressing a certain molecule are an appropriate model as target for the production of monoclonal antibodies, nanobodies and selection process of aptamers. Eukaryotic cells provide a suitable source for recombinant protein production with accurate folding and proper post translational modifications. Consistent with previous data, the HEK 293T cells are suitable source for this aim (23-26).

Kondratowicz *et al.* (13) have reported transient transfection of a TIM-1 expressing plasmid into HEK 293T cells have been resulted in TIM-1 surface expression in about 20% of the population. Also Moller-Tank *et al.* (14) have reached to 70% TIM-1 surface expression; whereas our results showed 88.15% of cells have stably expressed TIM-1 protein. This very high expression was obtained by

pcDNATM3.1/Hygro (+) vector, which contain cytomegalovirus promoter. Hence, these cells, as an available “cell display” source, could be used for production of specific molecules against TIM-1.

Funding/Support

This work is financially supported by a grant (no. 9299) from Immunology Research Center, Tabriz University of Medical Sciences.

References

1. Kane LP. T Cell Ig and mucin domain proteins and immunity. *J Immunol.* 2010;**184**:2743-2749. DOI: 10.4049/jimmunol.0902937
2. Freeman GJ, Casanovas JM, Umetsu DT, DeKruyff RH. *TIM* genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. *Immunol Rev.* 2010;**235**:172-189. DOI: 10.1111/j.0105-2896.2010.00903.x
3. Rennett PD. Novel roles for TIM-1 in immunity and infection. *Immunol Lett.* 2011;**141**:28-35. DOI: 10.1016/j.imlet.2011.08.003
4. McIntire JJ, Umetsu SE, Akbari O, Potter M, Kuchroo VK, Barsh GS, Freeman GJ, Umetsu DT, DeKruyff RH. Identification of *Tapr* (an airway hyperreactivity regulatory locus) and the linked *TIM* gene family. *Nat Immunol.* 2001;**2**:1109-1116.
5. McIntire JJ, Umetsu DT, De Kruyff RH. *TIM-1*, a novel allergy and asthma susceptibility gene. *Springer Semin Immunopathol.* 2004;**25**:335-348. DOI: 10.1007/s00281-003-0141-3
6. Rodriguez-Manzanet R, DeKruyff RH, Kuchroo VK, Umetsu DT. The costimulatory role of TIM molecules. *Immunol Rev.* 2009;**229**:259-270. DOI: 10.1111/j.1600-065X.2009.00772.x
7. Kuchroo VK, Umetsu DT, DeKruyff RH and Freeman GJ. The *TIM* gene family: emerging roles in immunity and disease. *Nat Rev Immunol.* 2003;**3**:454-462. DOI: 10.1038/nri1111
8. Meyers JH, Sabatos CA, Chakravarti S, Kuchroo VK. The *TIM* gene family regulates autoimmune and allergic diseases. *Trends Mol Med.* 2005;**11**:362-369. DOI: <http://dx.doi.org/10.1016/j.molmed.2005.06.008>
9. Angiari S, Donnarumma T, Rossi B, Dusi S, Pietronigro E, Zenaro E, Della Bianca V, Toffali L, Piacentino G, Budui S, Rennett P, Xiao S, Laudanna C, Casanovas JM, Kuchroo VK, Constantin G. TIM-1 glycoprotein binds the adhesion receptor P-selectin and mediates T cell trafficking during inflammation and autoimmunity. *Immunity.* 2014;**40**:542-553. DOI: 10.1016/j.immuni.2014.03.004
10. Jemielity S, Wang JJ, Chan YK, Ahmed AA, Li W, Monahan S, Bu X, Farzan M, Freeman GJ, Umetsu DT, DeKruyff RH, Choe H. TIM-family proteins promote infection of multiple enveloped viruses through virion-associated phosphatidylserine. *PLoS Pathog.* 2013;**9**:e1003232. DOI: 10.1371/journal.ppat.1003232
11. Lee HH, Meyer EH, Goya S, Pichavant M, Kim HY, Bu X, Umetsu SE, Jones JC, Savage PB, Iwakura Y, Casanovas JM, Kaplan G, Freeman GJ, DeKruyff RH, Umetsu DT. Apoptotic

- cells activate NKT cells through T Cell Ig-Like Mucin-Like-1 resulting in airway hyperreactivity. *J Immunol.* 2010;**185**:5225-5235. DOI: 10.4049/jimmunol.1001116
12. Perera-Lecoin M, Meertens L, Carnec X, Amara A. Flavivirus entry receptors: An update. *Viruses* 2014;**6**:69-88. DOI: 10.3390/v6010069
 13. Kondratowicz AS, Lennemann NJ, Sinn PL, Davey RA, Hunt CL, Moller-Tank S, Meyerholz DK, Rennert P, Mullins RF, Brindley M, Sandersfeld LM, Quinn K, Weller M, McCray PB Jr, Chiorini J, Maury W. T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebola virus and Lake Victoria Marburg virus. *Proc Natl Acad Sci USA.* 2011;**108**:8426-8431. DOI: 10.1073/pnas.1019030108
 14. Moller-Tank S, Kondratowicz AS, Davey RA, Rennert PD, Maury W. Role of the phosphatidylserine receptor TIM-1 in enveloped-virus entry. *J Virol.* 2013;**87**:8327-8341. DOI: 10.1128/JVI.01025-13
 15. Moller-Tank S, Albritton LM, Rennert PD, Maury W. Characterizing functional domains for TIM-mediated enveloped virus entry. *J Virol.* 2014;**88**:6702-6713. DOI: 10.1128/JVI.00300-14
 16. Ruffell B, DeNardo DG, Affara NI, Coussens M. Lymphocytes in cancer development: polarization towards pro-tumor immunity. *Cytokine Growth Factor Rev.* 2010;**21**:3-10. DOI: 10.1016/j.cytogfr.2009.11.002
 17. Froger A, Hall JE. Transformation of plasmid DNA into *E. coli* using the heat shock method. *J Vis Exp.* 2007;**6**:253. DOI: 10.3791/253
 18. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2^{-Delta}Delta C (T) Method. *Methods* 2001;**25**:402-408.
 19. Jiwaji M, Daly R, Pansare K, McLean P, Yang J, Kolch W, Pitt AR. The Renilla luciferase gene as a reference gene for normalization of gene expression in transiently transfected cells. *BMC Mol Biol.* 2010;**11**:103. DOI: 10.1186/1471-2199-11-103
 20. Xiao S, Najafian N, Reddy J, Albin M, Zhu C, Jensen E, Imitola J, Korn T, Anderson AC, Zhang Z, Gutierrez C, Moll T, Sobel RA, Umetsu DT, Yagita H, Akiba H, Strom T, Sayegh MH, DeKruyff RH, Khoury SJ, Kuchroo VK. Differential engagement of Tim-1 during activation can positively or negatively costimulate T cell expansion and effector function. *J Exp Med.* 2007;**204**:1691-1702. DOI: 10.1084/jem.20062498
 21. Encinas JA, Janssen EM, Weiner DB, Calarota SA, Nieto D, Moll T, Carlo DJ, Moss RB. Anti-T-cell Ig and mucin domain-containing protein 1 antibody decreases TH2 airway inflammation in a mouse model of asthma. *J Allergy Clin Immunol.* 2005;**116**:1343-1349. DOI: <http://dx.doi.org/10.1016/j.jaci.2005.08.031>
 22. Soo Hoo W, Jensen ER, Saadat A, Nieto D, Moss RB, Carlo DJ, Moll T. Vaccination with cell immunoglobulin mucin-I antibodies and inactivated influenza enhances vaccine-specific lymphocyte proliferation, interferon production and cross-strain reactivity. *Clin Exp Immunol.* 2006;**145**:123-129.
 23. Zhu J. Mammalian cell protein expression for biopharmaceutical production. *Biotechnol Adv.* 2012;**30**:1158-1170. DOI: 10.1016/j.biotechadv.2011.08.022
 24. Thomas P, Smart TG. HEK293 cell line: a vehicle for the expression of recombinant proteins. *J Pharmacol Toxicol Methods.* 2005;**51**:187-200.
 25. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. *J Exp Med.* 2005;**202**:473-477. DOI: 10.1084/jem.20050304
 26. Estacion M, Sinkins WG, Jones SW, Applegate MA, Schilling WP. Human TRPC6 expressed in HEK 293 cells forms non-selective cation channels with limited Ca²⁺ permeability. *J Physiol.* 2006;**572**:359-377.